Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study.
Journal of Affective Disorders January 30, 2026 Yao-Zu Li, Cai-Qun Zhao, Mu-Yan Zuo et al.
To evaluate the efficacy and safety of a multimodal rapid anti-depression therapy that combines esketamine treatment with dexmedetomidine patient-controlled sleep (PCSL) in patients with treatment-resistant depression (TRD). We retrospectively included 233 patients with TRD who received the multimodal treatment. Baseline clinical characteristics were collected. Follow-up assessments were...